Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2015—The Binding Site, through its arrangement with Arotec Diagnostics, offers an Ro (SSA) antigen designed for use as a component in solid phase ELISA-based immunoassay test procedures for the detection of anti-Ro (SSA) antibodies for use in research and in vitro diagnostic manufacturing applications.
April 2015—Genologics announced that GenomeDx Biosciences has implemented Genologics’ laboratory information management system, Clarity LIMS, to support whole transcriptome analysis workflows as part of GenomeDx’s mission to address unmet clinical needs in the management of prostate cancer. Headquartered in Vancouver, BC, GenomeDx will use Clarity LIMS in its CLIA-certified lab in San Diego.
April 2015—The NanoZoomer-SQ from Hamamatsu is a compact, single slide desktop scanner that converts a glass slide into a high-resolution digital image.
April 2015—The Clinical and Laboratory Standards Institute has published “Quality System Regulation for Laboratory-Developed Tests: A Practical Guide for the Laboratory.” The guide is intended to clarify how to implement the Quality System Regulation, 21 CFR 820, that may be required for some classifications of LDTs.
April 2015—Beckman Coulter Genomics has added stranded, ribodepletion and globin reduction library construction options to its existing RNA-Seq services. The Illumina TruSeq Stranded Total RNA Sample Prep Kit has been validated at Beckman Coulter Genomics for human, mouse, rat, and plant samples and automated on Beckman Coulter instruments to enable scalability and LIMS sample tracking. In addition, it includes the ability to work with samples derived from blood and formalin-fixed, paraffin-embedded tissue.
April 2015—This special formulation of Vector Labs’ VectaShield HardSet Mounting Medium, which prevents photobleaching of fluorescent proteins and fluorescent dyes, contains TRITC-phalloidin. Phalloidin is a bicyclic heptapeptide that specifically binds actin filaments within a cell.
April 2015—In an exclusive arrangement with Arotec Diagnostics, the Binding Site has added five antibodies to its line of in vitro diagnostic manufacturing and research products: Anti-NGAL, Anti-Calprotectin, Anti-Azurocidin, Anti-Neutrophil Elastase, and Anti-Neutrophil Lactoferrin.
April 2015—Dako, an Agilent Technologies company, and Ono Pharmaceutical announced a partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer.
March 2015—Illumina launched the MiSeq FGx Forensic Genomics System, a fully validated forensic next-generation sequencing system that simultaneously interrogates short tandem repeats and other valuable genetic markers, including single nucleotide polymorphisms, to provide informative DNA profiles. The system enables robust analysis of a range of genetic markers in a single workflow.
March 2015—Dako, an Agilent Technologies company, and Cell Signaling Technology have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products.
